{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:19:30Z","timestamp":1779171570066,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03475-2","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:28:14Z","timestamp":1767029294000},"page":"848-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct05618379","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yi","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daojun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maerhaba","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3475_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323. https:\/\/doi.org\/10.1001\/archneur.1995.00540290108025.","journal-title":"Arch Neurol"},{"key":"3475_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1212\/WNL.0000000000006026","volume":"91","author":"BT Darras","year":"2018","unstructured":"Darras BT, De Vivo DC. Precious SMA natural history data: a benchmark to measure future treatment successes. Neurology. 2018;91:337\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000006026.","journal-title":"Neurology"},{"key":"3475_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.12376\/j.issn.2097-0501.2023.03.009","volume":"2","author":"Rare Disease Society of Chinese Research Hospital Association, China Alliance for Rare Diseases, Beijing Society of Rare Disease Clinical Care and Accessibility, China Expert Group for Clinical Practice Guideline for Adolescent & Adults with Spinal Muscular Atrophy","year":"2023","unstructured":"Rare Disease Society of Chinese Research Hospital Association, China Alliance for Rare Diseases, Beijing Society of Rare Disease Clinical Care and Accessibility, China Expert Group for Clinical Practice Guideline for Adolescent & Adults with Spinal Muscular Atrophy. Clinical practice guideline for adolescent & adults with spinal muscular atrophy. J Rare Dis. 2023;2:377\u201397. https:\/\/doi.org\/10.12376\/j.issn.2097-0501.2023.03.009.","journal-title":"J Rare Dis"},{"key":"3475_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, McGovern VL, Avenarius MR, et al. Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet. 2019;138:241\u201356. https:\/\/doi.org\/10.1007\/s00439-019-01983-0.","journal-title":"Hum Genet"},{"key":"3475_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mus.27519","volume":"65","author":"N Rad","year":"2022","unstructured":"Rad N, Cai H, Weiss MD. Management of spinal muscular atrophy in the adult population. Muscle Nerve. 2022;65:498\u2013507. https:\/\/doi.org\/10.1002\/mus.27519.","journal-title":"Muscle Nerve"},{"key":"3475_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5863\/1551-6776-24.3.194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24:194\u2013203. https:\/\/doi.org\/10.5863\/1551-6776-24.3.194.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"3475_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","volume":"9","author":"R Mahajan","year":"2019","unstructured":"Mahajan R. Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever. Int J Appl Basic Med Res. 2019;9:127\u20138. https:\/\/doi.org\/10.4103\/ijabmr.IJABMR_190_19.","journal-title":"Int J Appl Basic Med Res"},{"key":"3475_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","volume":"12","author":"H Ratni","year":"2021","unstructured":"Ratni H, Scalco RS, Stephan AH. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med Chem Lett. 2021;12:874\u20137. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00659.","journal-title":"ACS Med Chem Lett"},{"key":"3475_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5.","journal-title":"Lancet Neurol"},{"key":"3475_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acn3.51514","volume":"9","author":"M Pane","year":"2022","unstructured":"Pane M, Coratti G, Pera MC, et al. Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy. Ann Clin Transl Neurol. 2022;9:404\u20139. https:\/\/doi.org\/10.1002\/acn3.51514.","journal-title":"Ann Clin Transl Neurol"},{"key":"3475_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis. 2019;6:453\u201365. https:\/\/doi.org\/10.3233\/JND-190416.","journal-title":"J Neuromuscul Dis"},{"key":"3475_CR12","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1007\/s00415-024-12567-y","volume":"271","author":"N Wang","year":"2024","unstructured":"Wang N, Hu Y, Jiao K, et al. Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study. J Neurol. 2024;271:6004\u201314. https:\/\/doi.org\/10.1007\/s00415-024-12567-y.","journal-title":"J Neurol"},{"key":"3475_CR13","unstructured":"Dai Y, Zhao Y, Shang H, et al. A national registry for adult patients with spinal muscular atrophy in China: preliminary report of design, progress and patient characteristics [abstract]. In: The 21st annual meeting of Asian Oceanian Myology Center. Shanghai, China; 2023"},{"key":"3475_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s1090-3798(03)00060-6","volume":"7","author":"M Main","year":"2003","unstructured":"Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7:155\u20139. https:\/\/doi.org\/10.1016\/s1090-3798(03)00060-6.","journal-title":"Eur J Paediatr Neurol"},{"key":"3475_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374. https:\/\/doi.org\/10.1002\/mus.25430.","journal-title":"Muscle Nerve"},{"key":"3475_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","volume":"54","author":"S Dunaway Young","year":"2016","unstructured":"Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836\u201342. https:\/\/doi.org\/10.1002\/mus.25120.","journal-title":"Muscle Nerve"},{"key":"3475_CR17","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/acn3.51411","volume":"8","author":"MC Pera","year":"2021","unstructured":"Pera MC, Coratti G, Bovis F, et al. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8:1622\u201334. https:\/\/doi.org\/10.1002\/acn3.51411.","journal-title":"Ann Clin Transl Neurol"},{"key":"3475_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100862","volume":"39","author":"R G\u00fcnther","year":"2024","unstructured":"G\u00fcnther R, Wurster CD, Brakemeier S, et al. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Region Health Eur. 2024;39:100862. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100862.","journal-title":"Lancet Region Health Eur"},{"key":"3475_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-020-1339-3","volume":"15","author":"HWY Wan","year":"2020","unstructured":"Wan HWY, Carey KA, D\u2019Silva A, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet J Rare Dis. 2020;15:70. https:\/\/doi.org\/10.1186\/s13023-020-1339-3.","journal-title":"Orphanet J Rare Dis"},{"key":"3475_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/PRM-160360","volume":"9","author":"S Dunaway","year":"2016","unstructured":"Dunaway S, Montes J, McDermott MP, et al. Physical therapy services received by individuals with spinal muscular atrophy (SMA). J Pediatr Rehabil Med. 2016;9:35\u201344. https:\/\/doi.org\/10.3233\/PRM-160360.","journal-title":"J Pediatr Rehabil Med"},{"key":"3475_CR21","unstructured":"Kelly K, Dahdul M, Nelson L, et al. Physical therapy use in treated and untreated children and adults with spinal muscular atrophy (SMA): a descriptive analysis using US claims [abstract]. In: MDA clinical & scientific conference. Orlando, United States; 2024."},{"key":"3475_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.31083\/j.fbl2706179","volume":"27","author":"A Mirea","year":"2022","unstructured":"Mirea A, Leanca L, Onose G, et al. Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome. Front Biosci Landmark Ed. 2022;27:179. https:\/\/doi.org\/10.31083\/j.fbl2706179.","journal-title":"Front Biosci Landmark Ed."},{"key":"3475_CR23","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;11:e317\u201327. https:\/\/doi.org\/10.1212\/CPJ.0000000000001033.","journal-title":"Neurol Clin Pract"},{"key":"3475_CR24","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91:1166\u201374. https:\/\/doi.org\/10.1136\/jnnp-2020-323822.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3475_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.27384","volume":"64","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pera MC, Montes J, et al. Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle Nerve. 2021;64:552\u20139. https:\/\/doi.org\/10.1002\/mus.27384.","journal-title":"Muscle Nerve"},{"key":"3475_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cnp.2024.04.002","volume":"9","author":"PE Barkhaus","year":"2024","unstructured":"Barkhaus PE, Nandedkar SD, de Carvalho M, Swash M, St\u00e5lberg EV. Revisiting the compound muscle action potential (CMAP). Clin Neurophysiol Pract. 2024;9:176\u2013200. https:\/\/doi.org\/10.1016\/j.cnp.2024.04.002.","journal-title":"Clin Neurophysiol Pract"},{"key":"3475_CR27","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/pharmaceutics14102074","volume":"14","author":"M Axente","year":"2022","unstructured":"Axente M, Mirea A, Sporea C, et al. Clinical and electrophysiological changes in pediatric spinal muscular atrophy after 2 years of nusinersen treatment. Pharmaceutics. 2022;14:2074. https:\/\/doi.org\/10.3390\/pharmaceutics14102074.","journal-title":"Pharmaceutics"},{"key":"3475_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","volume":"92","author":"D Kariyawasam","year":"2020","unstructured":"Kariyawasam D, D\u2019Silva A, Howells J, et al. Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen. J Neurol Neurosurg Psychiatry. 2020;92:78\u201385. https:\/\/doi.org\/10.1136\/jnnp-2020-324254.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3475_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/DDDT.S449066","volume":"18","author":"D Li","year":"2024","unstructured":"Li D, Sun N, Xiang L, et al. Neurophysiological characteristics in type II and type III 5q spinal muscular atrophy patients: impact of nusinersen treatment. Drug Des Devel Ther. 2024;18:953\u201365. https:\/\/doi.org\/10.2147\/DDDT.S449066.","journal-title":"Drug Des Devel Ther"},{"key":"3475_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.arcped.2023.08.011","volume":"31","author":"M Richard","year":"2024","unstructured":"Richard M, Barrois R, Desguerre I, et al. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen. Arch Pediatr. 2024;31:26\u201331. https:\/\/doi.org\/10.1016\/j.arcped.2023.08.011.","journal-title":"Arch Pediatr"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03475-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03475-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03475-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:43Z","timestamp":1771268623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03475-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3475"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03475-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Li Zhang and Maerhaba Mai are employees of Biogen and may hold stock in Biogen. Ken Chen is an employee of IQVIA. Yi Dai, Xiaoli Yao, Wenhua Zhu, Yuying Zhao, Huifang Shang, Juanjuan Chen, Qiang Meng, Yaling Liu, Wanjin Chen, Liqiang Yu, Lu Shen, Daojun Hong, and Liying Cui declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study protocol was approved by the ethics committees of each participating site. The study was conducted in accordance with the Declaration of Helsinki. Informed consents of all participants (or their legally authorized guardians) were obtained in accordance with local institutions\u2019 regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}